Gossamer Bio, Inc.

Listed Company

GOSSCIK 0001728117NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$48.47M

Net Income

$-170.37M

Total Assets

$172.25M

Equity

$-122.76M

Shares Out

234.70M

Op. Cash Flow

$-171.27M

Business

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for pulmonary hypertension, including pulmonary arterial hypertension and PH associated with interstitial lung disease. Its main product candidate is seralutinib, an investigational inhaled small-molecule PDGFR, CSF1R and c‑KIT inhibitor being evaluated in Phase 3 trials, supported by preclinical and clinical development programs and an inhalation delivery system. Key business activities include global clinical development, regulatory engagement, licensing and collaboration arrangements (notably with Chiesi and Pulmokine) and reliance on third‑party manufacturing. The company pursues development and potential U.S. commercialization while partnering for ex‑U.S. rights, conducting global trials and targeting specialist centers of excellence for patient treatment and distribution.

Summary from filing dated 2025-03-13

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenue	48	115	0	0	—
Research and development	174	138	135	171	170
In process research and development	7	0	10	—	—
General and administrative	38	36	38	48	46
Total operating expenses	219	175	184	219	216
Loss from operations	−171	−60	−184	−219	−216
Interest income	2	2	2	2	761,000
Interest expense	−11	−12	−14	−14	—
Other income, net	9	14	15	2	799,000
Total other income, net	270,000	4	4	−11	−18
Loss before provision (benefit) for income taxes	−170	−56	−180	−229	—
Provision (benefit) for income taxes	−88,000	893,000	0	0	—
Net loss	−170	−57	−180	−229	−234
Foreign currency translation	−6	1	33,000	−544,000	−329,000
Unrealized income (loss) on marketable securities	−90,000	89,000	191,000	−75,000	−225,000
Other comprehensive income (loss)	−6	2	224,000	−619,000	−554,000
Comprehensive loss	−177	−55	−180	−230	−235
Net loss per share, basic (in dollars per share)	−0.75	−0.25	−1.18	−2.71	−3.13
Net loss per share, diluted (in dollars per share)	−0.75	−0.25	−1.18	−2.71	−3.13
Weighted average common shares outstanding, basic (in shares)	229	226	153	85	75
Weighted average common shares outstanding, diluted (in shares)	229	226	153	85	75

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	38	46	32	112	183
Marketable securities	99	248	264	144	142
Receivable from contracts with collaborators	12	5	0	—	—
Prepaid expenses and other current assets	18	10	10	6	6
Total current assets	168	310	307	262	332
Property and equipment, net	64,000	10,000	2	4	5
Operating lease right-of-use assets	4	5	3	6	5
Other assets	408,000	283,000	618,000	680,000	1
Total assets	172	315	312	272	344
Accounts payable	6	2	6	1	3
Accrued research and development expenses	22	10	8	16	16
Current contract liabilities	20	17	0	—	—
Accrued expenses and other current liabilities	16	15	27	21	20
Total current liabilities	63	45	52	49	40
Long-term convertible senior notes	199	198	197	196	150
Operating lease liabilities - long-term	3	4	144,000	3	3
Long-term contract liabilities	30	39	0	—	—
Total liabilities	295	286	249	260	222
Commitments and contingencies (Note 11)	—	—	—	—	—
Common stock, $0.0001 par value; 700,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 233,677,057 shares issued and outstanding as of December 31, 2025, and 226,604,138 shares issued and outstanding as of December 31, 2024	24,000	23,000	23,000	10,000	8,000
Additional paid-in capital	1,321	1,297	1,275	1,045	933
Accumulated deficit	−1,439	−1,269	−1,212	−1,032	−812
Accumulated other comprehensive income (loss)	−5	1	−350,000	−574,000	45,000
Total stockholders' equity (deficit)	−123	29	63	12	121
Total liabilities and stockholders' equity (deficit)	172	315	312	272	344

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−170	−57	−180	−229	−234
Depreciation and amortization	24,000	833,000	2	2	2
Stock-based compensation expense	11	21	29	43	32
In process research and development expenses	7	0	10	—	—
Amortization of operating lease right-of-use assets	978,000	3	3	3	3
Amortization of long-term debt discount and issuance costs	985,000	1	1	1	7
Amortization of premium on investments, net of accretion of discounts	−7	−13	−9	−1	339,000
Net realized gain on investments	−5,000	0	0	0	0
Loss on disposal of property and equipment	0	806,000	726,000	0	20,000
Receivable from contracts with collaborators	−7	−5	0	0	—
Prepaid expenses and other current assets	−8	62,000	−4	296,000	3
Other assets	−125,000	335,000	62,000	400,000	−53,000
Operating lease liabilities	−961,000	−3	−3	−3	−4
Accounts payable	−3	−2	4	−2	−4
Accrued expenses	1	−11	−835,000	−2	736,000
Accrued research and development expenses	11	3	−8	−579,000	6
Accrued compensation and benefits	−784,000	2	−3	2	−278,000
Contract liabilities	−6	56	0	0	—
Accrued interest expense	0	−135,000	−97,000	−1,000	−28,000
Net cash used in operating activities	−171	−3	−159	−187	−189
Purchase of marketable securities	−227	−495	−442	−238	−152
Maturities of marketable securities	376	524	331	238	36
Sales of marketable securities	7	0	0	0	0
Purchase of property and equipment	−79,000	0	0	−410,000	−2
Net cash provided by (used in) investing activities	156	29	−111	−1	−117
Proceeds from issuance of common stock and warrants in a private offering, net of offering costs	0	0	201	120	0
Proceeds from issuance of common stock under Employee Stock Purchase Plan	840,000	629,000	444,000	1	1
Proceeds from the exercise of stock options	2	0	0	2	2
Proceeds from the exercise of warrants	4	0	0	—	—
Proceeds from issuance of equity option pursuant to stock purchase agreement	0	464,000	0	0	—
Principal repayments of long-term debt	0	−13	−12	−6	0
Net cash provided by (used in) financing activities	6	−11	190	117	3
Effect of exchange rate changes on cash and cash equivalents	141,000	−102,000	110,000	−517,000	−165,000
Net increase (decrease) in cash and cash equivalents	−8	14	−80	−71	−303
Cash paid for interest	10	11	12	13	13
Right-of-use assets obtained in exchange for lease liabilities	0	5	0	3	0
Change in unrealized gain (loss) on marketable securities, net	−90,000	89,000	191,000	−75,000	−225,000

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro